Mesenchymal stem cell (MSC) therapy and insulin-like growth factor (IGF)-1 (in combination with IGF-binding protein 3 [IGFB3]) are the new investigational agents that are being explored currently to prevent BPD.Figure 2 denotes the new and emerging therapies for the management and prevention of BPD. The gene discussed is IGFBP3; the disease is bronchopulmonary dysplasia.